Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

Aeglea receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the mid-twenties. Immedica obtains exclusive commercialization rights in Europe and several Middle Eastern countries.Austin, Texas, and Stockholm, March 22, 2021 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a novel, recombinant

Höegh LNG: Bondholder's meeting approves amendments to bond terms

Hamilton, Bermuda 22 March 2021 - Höegh LNG Holdings Ltd. ("Höegh LNG" or the "Company") announced today that holders of the Company’s senior unsecured bond issues maturing in February 2022 (ISIN NO 0010782949) and January 2025 (ISIN NO 0010873755) (the "Bond Issues") have approved the Amendment Proposal as set out in the attachment to the press releases dated 8 March 2021 and 22 March 2021. The Amendment Proposal includes certain amendments to the bond terms related to the earlier announced offer from Leif Höegh & Co. Ltd. (“LHC”) and funds managed by Morgen Stanley Infrastructure Partners

Helbio has received an order worth 70,000 EUR from University of Groningen

Metacon subsidiary Helbio has received an order from the University of Groningen in the Netherlands for a reactor apparatus for studies in the field of catalytic hydrogen production. The order value is in the region of EUR 70,000.For further information, please contact CEO Christopher Tornblom, phone +44 7827 509544 or e-mail info@metacon.se This information is information that Metacon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13:20 CET on March 22,

Shawbrook Bank supports new client 4Syte Structured Finance with a revolving credit facility

- Facility will support the continued growth of the 4Syte Structured Finance secured SME portfolio - Since launching in 2019, 4Syte Structured Finance has deployed over £20m in UK SME loan facilities and aided in the development of over 100 businessesLondon: 22/03/2021 Shawbrook Bank has provided a revolving credit facility to 4Syte Structured Finance, a Chelmsford-based lending institution and part of the 4Syte Group of companies, to support the growth of its secured SME loan portfolio.  The wider 4Syte Group was founded in 2016 and is one of the UK's leading secured SME lenders,

Bergs Timber's Swedish subsidiary Bitus AB invests and expands the production capacity for Linax.

Linax is Bitus' own brand for linseed oil impregnated wood that is part of our product area Wood Protection. Linax has good properties for durability in color, shape and is mainly used as a deck, panel for detached houses, roofs and outdoor furniture. Demand for Linax is increasing and Bitus will now invest 22 million SEK to increase production from the current approx. 5000 m3 / year to 15 000 m3 / year. A new facility will be built in connection with the current production unit in Nybro, outside Kalmar. It will be ready by the turn of the year 2021/2022. – After the investment, the

Notice to Annual General Meeting of Remedy Entertainment Plc

Remedy Entertainment Plc | Company announcement 2:00 pm (EET) 22 March 2021 Notice to Annual General Meeting of Remedy Entertainment Plc Notice is given to the shareholders of Remedy Entertainment Plc to the Annual General Meeting to be held on Wednesday 14 April 2021 at 9:00 am (EET) at the Company’s office at Luomanportti 3, 02200 Espoo, Finland. The shareholders of the Company and their proxy representatives can only participate in the meeting and exercise the shareholder’s rights by voting in advance as well as by submitting counterproposals and asking questions in advance in

Annual Report, Board of Directors’ Report and Financial Statements for 2020 have been published

Remedy Entertainment Plc | Company announcement 2:00 pm (EET) 22 March 2021 Annual Report, Board of Directors’ Report and Financial Statements for 2020 have been published Remedy Entertainment Plc has published its Annual Report, Board of Directors’ Report and Financial Statements for 2020 at https://investors.remedygames.com The Annual Report, Board of Directors’ Report and Financial Statements for 2020 are also available as attachments of this company announcement. MORE INFORMATION Tero Virtala, Chief Executive OfficerPhone: +358 9 435 5040Email: tero.virtala@

Hansku Vihervaara appointed Head of Marketing for Construction and Industrial Adhesives and Fireproofing at Kiilto

Kiilto strengthens its marketing function by appointing Hansku Vihervaara Head of Marketing for Construction and Industrial Adhesives and Fireproofing, effective 29 March, 2021.Hansku Vihervaara will be responsible for the marketing of the Kiilto's Construction and Industrial Adhesives and Fireproofing business areas, as well as the development of the Kiilto Pro brand internationally in these business areas. Hansku has a strong professional background in B2B marketing of industrial business internationally. We warmly welcome Hansku to Kiilto and wish her all the best in the new role!

Oncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network®

STOCKHOLM — March 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that PEPAXTO[®] (melphalan flufenamide) has been included in the new Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network[®] (NCCN) in Oncology. PEPAXTO, in combination with dexamethasone, was granted accelerated approval by the FDA on February 26, 2021, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received

Nordic Nanovector ASA – Resolution to increase the share capital in connection with the repair offering and terms of the repair offering

Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 22 March 2021 Reference is made to the stock exchange announcement from Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") published on 23 February 2021 regarding the successfully completed private placement raising approximately NOK 361 million in gross

A change in Pihlajalinna Plc’s Management Team

Pihlajalinna Plc                   Stock exchange release                       22 March 2021 at 1.15 p.m. A change in Pihlajalinna Plc’s Management Team Pihlajalinna Plc has appointed Antti-Jussi Aro, M.Sc., as the new Chief Information Officer and member of the Management Team. Aro will take up the responsibilities and join the Management Team on 3 May 2021. Prior to this, Antti-Jussi Aro (b. 1983) was the Chief Digital Officer of Jääkiekon SM-liiga Oy. He has also served in international duties at Accenture and AbbVie. Aro graduated from Aalto University with a M.Sc. in

Nordic Nanovector ASA: Extraordinary general meeting held

Oslo, Norway, 22 March 2021 Nordic Nanovector ASA (the "Company") announces that an extraordinary general meeting in the Company was held today at the Company's offices in Kjelsåsveien 168B, 0884 Oslo. The extraordinary meeting approved all items on the agenda, including the authorisation to the Board of Directors to increase the share capital in connection with a potential repair offering as announced on 23 February 2021 and 1 March 2021. The minutes from the extraordinary general meeting are attached and are also available at www.nordicnanovector.com. As previously announced, a

Linxon successfully energized the Shams substation in Dubai, UAE

Linxon has successfully energized the Shams 400/132 kV substation in Dubai, which will transport solar power from the Mohammed bin Rashid Al Maktoum (MBR) Solar Park into the Dubai electrical grid.Both the Shams substation and the MBR solar generating park are owned by DEWA (the Dubai Electricity and Water Authority); they are located inland, ca. 50 kilometers south of Dubai. Once fully operational the combined facilities will have an overall capacity of more than 2,000 megavolt amperes (MVA) thereby delivering a key element of Dubai’s renewable energy strategy. “The collaboration with

Qred Holding AB (publ) instigates a written procedure to permit delisting of its senior secured bonds 2019/2022 from trading on regulated exchanges and multilateral trading facilities

Qred Holding AB (publ), Reg. No. 559031-0685 (the “Company”), has instructed Nordic Trustee & Agency AB (publ) (the “Agent”) to instigate a written procedure (the “Written Procedure”) in respect of the senior secured bonds 2019/2022 with ISIN SE0012507267 (the “Bonds”), seeking approval from holders of the Bonds to amend the terms and conditions to permit delisting the Bonds from trading on regulated exchanges and multilateral trading facilities.   This measure is taken in light of regulatory guidance recently issued by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen)

Notice of Annual General Meeting in SaltX Technology Holding AB (publ)

The shareholders of SaltX Technology Holding AB (publ), Reg. No. 556917-6596 (“SaltX” or the “company”) are hereby summoned to the Annual General Meeting on Thursday, 22 April 2021.In light of the corona pandemic and in order to minimize any risk of spreading the coronavirus, the Board of Directors of the company has decided that the Annual General Meeting is to be held only through postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations. This means that the Annual General

Smart to power cell sites with green energy through fuel cell technology from SerEnergy

In an effort to transition to more sustainable and environment-friendly solutions, while providing connectivity to more communities, Smart Communications, Inc. (Smart) will roll out fuel cell sites in challenged-grid areas nationwide starting Q2 2021 until the end of the year. As the wireless arm of the Philippines' largest integrated telecommunications company, PLDT Inc., Smart's shift to green energy follows the announcement of the Department of Energy in Q4 of 2020 that the Filipino government will no longer accept proposals to build new coal power plants, from the new Energy

Resolutions of Citycon Oyj’s Annual General Meeting

CITYCON OYJ  Stock Exchange Release           22 March 2021 at 12:45 hrsCitycon Oyj’s Annual General Meeting took place in Espoo, Finland, today 22 March 2021. In order to prevent the spread of the COVID-19 pandemic, the Annual General Meeting was held without shareholders’ and their proxy representatives’ presence at the venue of the meeting. The shareholders of the company participated in the meeting and exercised their shareholder’s rights by voting in advance. The General Meeting approved all the proposals made by the Board of Directors to the General Meeting.The General Meeting

Notice of the Annual General Meeting in Wihlborgs Fastigheter AB (publ)

The shareholders of Wihlborgs Fastigheter AB (publ) are hereby invited to attend the Annual General Meeting on Tuesday, 27 April 2021.Due the coronavirus pandemic, and taking into consideration the government’s restrictions and recommendation that public gatherings be avoided, the AGM will be conducted solely by way of advance voting (postal voting) with the support of temporary statutory requirements. This means that it will not be possible to attend this year’s AGM in person or via a proxy. Wihlborgs Fastigheter AB welcomes all shareholders to exercise their voting rights at the AGM by

Observe Medical receives follow-up order to deliver additional quantity of safety needles to a hospital region in the Nordic market

Oslo 22 March 2021 – Observe Medical ASA (OSE: OBSRV), today announces that Observe Medical Group has received a follow-up order to deliver additional quantity of safety needles to a hospital region in the Nordic market. The follow-up order represents a value of 4.2 mSEK, with planned delivery of the products during Q3 this year. The original order, with a value of 5.8 mSEK was announced on January 29 see Link . Thus, the total order

Morgan Stanley’s indirect holding in Tikkurila decreased to 4.93%

Tikkurila OyjMajor Shareholder Announcement22 March 2021 at 12.25 p.m. (EET) Tikkurila Oyj (business ID 0197067-4) has on March 19, 2021 received a notification pursuant to the Finnish Securities Markets Act, Chapter 9, Section 10, from Morgan Stanley. The indirect holding of the funds and accounts managed by Morgan Stanley in the shares and financial instruments of Tikkurila Oyj decreased below 5 percent threshold and is now 4.93%, as a consequence of the trades executed on March 18, 2021. Morgan Stanley’s position according to their notification: Full name of Shareholders:

Veidekke ASA: Presentation of the construction and civil engineering market outlook 2021-2022

Veidekke ASA presents outlooks for the Scandinavian construction and civil engineering markets 2021-2022 on Thursday 25 March at 08:30 CET. The presentation document will be made available on Veidekke's corporate website  at 07:30 CET. To comply with the strict covid-19 infection control measures, the event is accessible via webcast  only. Veidekke welcomes questions from the audience via e-mail.

The National SciLifeLab-KAW COVID-19 Research program is extended through funding from KAW

Press release from SciLifeLabIn March 2020, SciLifeLab launched a national COVID-19 research program together with the Knut and Alice Wallenberg Foundation (KAW). Now, the program will be prolonged and extended through a new donation of 50 million SEK from KAW.“Almost one year have passed since the launch of the national research program on COVID-19. It has been amazing to see the collective effort and new collaborations that was initiated between researchers at our universities in a very short time. Present results are remarkable and applicable in the current crisis, but more research is

Shape Robotics changes certified adviser

Company Announcement No. 21-2021Copenhagen, March 22, 2021 Shape Robotics has engaged Norden CEF as new certified adviser, effective from April 1st 2021. “We are pleased to start working with Norden CEF as our new certified adviser. Their experienced team and large network will support our continued growth journey as well as help us meet the regulatory obligations at Nasdaq First North” says David Johan Christensen, CEO. Norden CEF has assisted several companies on Nasdaq First North Growth Market. John Norden is certified advisor for Alefarm Brewing, FOM Technologies, Dataproces

Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved

GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that a notice that a Clinical Use Patent for the drug candidate arfolitixorin will be approved in Europe. The patent covers a dose regimen for treating solid tumors, such as colorectal, stomach, breast and liver cancer and expires in 2038.The patent application that will be granted , EP18150457.2, includes a dose regimen involving two or more injections of arfolitixorin in combination with 5-fluorouracil (5-FU). These two agents may also be given in combination

There are no items matching the current filter
There are no more items matching the current filter
Back to top